Objectives: For reasons not well understood, antibacterials can yield lower cure rates in renally impaired patients. We explored this subject for the novel antibacterial ceftolozane/tazobactam.
Introduction
Ceftolozane/tazobactam is a b-lactam/b-lactamase-inhibitor combination approved for complicated intra-abdominal infections (cIAIs) and complicated urinary tract infections (cUTIs), including pyelonephritis. [1] [2] [3] It is active against a wide range of pathogens, including MDR and XDR Pseudomonas aeruginosa and ESBLproducing Enterobacteriaceae. [4] [5] [6] Several antibacterial clinical trials reported lower cure rates in patients with renal impairment (RI). Little is known about what may have caused these differences, [7] [8] [9] [10] [11] but such an understanding is crucial to achieve better treatment outcomes. We analysed data from two randomized controlled trials with ceftolozane/tazobactam to evaluate: (i) the effect of RI on efficacy and safety outcomes; and (ii) patient and clinical factors that potentially influenced these outcomes. 
Methods

Analysis populations and endpoints
This article describes predefined and exploratory analyses of the ASPECT-cIAI (NCT01445665/NCT01445678) and ASPECT-cUTI (NCT01345929/NCT01345955) trials. 1, 2 The ASPECT-cIAI microbiological intent-to-treat (MITT) population comprised all randomized patients, with ! 1 intra-abdominal pathogen, regardless of receipt of study drug or susceptibility to study drug. The ASPECT-cUTI microbiological modified intent-to-treat (mMITT) population included all patients who received study medication and had ! 1 uropathogen. The microbiologically evaluable (ME) populations comprised patients who received study drug, adhered to protocol and had any uropathogen (ASPECT-cUTI) or susceptible intra-abdominal pathogen (ASPECT-cIAI). Patients with indeterminate responses (i.e. data not available for efficacy evaluation for any reason and/or circumstances precluded classification as cure/failure) were considered treatment failures in the MITT/mMITT analyses, and were excluded from the ME population as per the study protocol.
We evaluated two subpopulations, defined a priori in the statistical analysis plan (SAP): patients with moderate RI [creatinine clearance (CL CR ) 30-50 mL/min] and mild/no RI (CL CR > 50 mL/min) (Cockcroft-Gault). In these subpopulations, we compared: clinical cure rate at test-of-cure (TOC) 24-32 days from therapy initiation in the MITT and ME populations (ASPECTcIAI); and composite cure rates (both clinical and microbiological response) in the mMITT population and clinical cure rates in ME population, both at TOC 5-9 days post-therapy (ASPECT-cUTI). End-of-therapy (EOT) visits occurred within 24 h of stopping study drug.
Safety was monitored from study initiation until late follow-up (LFU), 38-45 days after first dose in ASPECT-cIAI and 28-35 days after last dose in ASPECT-cUTI, by review of treatment-emergent adverse events (TEAEs), vital signs, physical examination findings and clinical laboratory results.
Statistical analysis
The impact of moderate versus mild/no RI on clinical outcomes was examined through logistic regression. Classification and regression tree (CART) analysis was used to confirm the predefined baseline CL CR breakpoint. Baseline/disease characteristics, AEs and laboratory results were evaluated using descriptive statistics. Statistical analyses were performed using SAS version 9.1.3 (SAS Institute, Cary, NC, USA) and R version 3.2.4.
Results
Patient disposition/baseline characteristics
Overall, 4.5% (36/806) of cIAI patients and 7.3% (58/795) of cUTI patients had moderate RI. Almost twice as many moderate RI cIAI patients received ceftolozane/tazobactam (n ¼ 23) than meropenem (n ¼ 13); the corresponding distribution in cUTI patients was similar between treatment arms (n ¼ 31 ceftolozane/tazobactam; n ¼ 27 levofloxacin). All patients with moderate RI received the correctly adjusted ceftolozane/tazobactam or comparator agent dose according to protocol definitions.
Significant demographic differences existed between moderate and mild/no RI patients ( 
Efficacy
Response rates in cUTI mMITT patients were 81% (25/31) with ceftolozane/tazobactam and 78% (21/27) with levofloxacin. Response rates for cIAI MITT patients with moderate RI were 48% (11/23) with ceftolozane/tazobactam and 69% (9/13) with meropenem. The cIAI MITT population was imbalanced in terms of moderate RI patients with indeterminate TOC responses: 39.1% (9/23) ceftolozane/tazobactam; 7.7% (1/13) meropenem ( Figure S1 ). Among those, 2/9 ceftolozane/tazobactam patients had missing TOC visits, but were deemed clinical cures at EOT and LFU; therefore, these patients would likely have been clinical cures at TOC. Six patients with indeterminate responses withdrew early from the study. Similar imbalances were not observed in cUTI patients. In moderate RI patients in the ME populations, response rates in cIAI patients were similar between ceftolozane/tazobactam (72.7%) and meropenem (71.4%) and in cUTI patients were 87% with ceftolozane/tazobactam and 80% with levofloxacin ( Figure S2 ). For cUTI MITT patients, composite cure rates were 78.5% (ceftolozane/tazobactam) versus 69.0% (levofloxacin) in mild/no RI and 61.3% (ceftolozane/tazobactam) versus 59.3% (levofloxacin) in moderate RI.
Regardless of treatment, cIAI moderate RI patients had significantly greater risk of treatment failure compared with mild/no RI [relative risk (RR) ¼ 3.32, 44.4% versus 13.4%, P < 0.001]. Higher failure risk was also seen in cIAI patients ! 65 years (RR ¼ 2.12, 24.9% versus 11.8%, P < 0.001), with type 2 diabetes mellitus (RR ¼ 1.77, 24.6% versus 13.9%, P ¼ 0.019) or with bowel infections (RR ¼ 2.18, 26.1% versus 12.0%, P < 0.001). In cUTI patients, regardless of treatment arm, patients ! 65 years (RR ¼ 2.21, 16.2% versus 7.4%, P < 0.001), with type 2 diabetes mellitus (RR ¼ 1.94, 16.0% versus 8.3%, P < 0.001) or with moderate RI (RR ¼ 2.39, 20.7% versus 8.7%, P ¼ 0.0028) had higher clinical failure risk. CART analysis demonstrated that cIAI patients with CL CR 53.1 mL/min had significantly lower cure rates compared to CL CR > 53.1 mL/min (62.1% versus 87.3%, P < 0.001) and cUTI patients with CL CR 57.4 mL/min had significantly lower cure rates compared to CL CR > 57.4 mL/min (79.6% versus 91.9%, P < 0.001).
Safety
The incidence of TEAEs in moderate RI patients was 41/70 (58.6%) in the pooled ceftolozane/tazobactam and 35/54 (64.8%) in the pooled comparator populations. Most common TEAEs in ceftolozane/tazobactam and comparator-treated patients were hypertension and anaemia (5.7% each) and diarrhoea (14.8%), respectively. Across studies, serious AEs (most common: infections/infestations) were more frequent in moderate compared with mild/no RI patients (16.9% versus 4.5%, P < 0.001).
Five moderate RI cIAI patients died. Reasons for death, all deemed unrelated to study drug, in the ceftolozane/tazobactam arm were: myocardial infarction due to chronic diseases (n ¼ 1); septic shock/multi-organ failure (MOF) due to post-surgical wound infection (n ¼ 1); ischaemic shock/MOF due to chronic diseases (n ¼ 1); and cardiac failure due to suspected embolism (n ¼ 1). One meropenem patient died due to acute cardiovascular insufficiency. Among moderate RI cUTI patients, there was one death in the ceftolozane/tazobactam arm due to bladder cancer and MOF and none in the levofloxacin arm.
Ceftolozane/tazobactam in renal impairment JAC NA 74 year old female with ongoing medical history of arterial HTN, COPD, type 2 diabetes mellitus and with past medical history of RI. Patient had outcome of cure at EOT, but died from MI 14 days after study drug discontinuation prior to TOC visit. Only Enterococcus faecalis was isolated at baseline (resistant to C/T) and patient did not receive concomitant adjunctive Gram-positive therapy. C/T cIAI 2 days/2 doses Early withdrawal due to AE of haemorrhagic shock.
NA 92 year old female with ongoing medical history of scoliosis, osteoporosis, asthma, atrial fibrillation and inguinal hernia. Haemorrhagic shock was related to enoxaparin administration. C/T cIAI 10 days/28 doses Early withdrawal by patient.
Renal function improved to normal on day 2 and dose was adjusted accordingly.
47 year old male with past medical history of RI. Patient withdrew consent; no additional information on why consent was withdrawn. Only other information available is that the patient suffered from delirium tremens due to alcohol withdrawal from day 3 to day 8. It is possible that after the delirium tremens had resolved, the patient wanted to leave the hospital and the study.
(continued)
Ceftolozane/tazobactam in renal impairment JAC Discussion cIAI and cUTI patients with CL CR 50 mL/min were over three and two times more likely, respectively, to fail regardless of therapy; retrospective CART analysis suggested that this CL CR breakpoint (defined a priori) was appropriate. In the MITT population, the lower treatment response in cIAI moderate RI patients administered ceftolozane/tazobactam was primarily driven by an imbalance in indeterminate responses at TOC (Table 2 ). In the ME analysis, response rates were similar between ceftolozane/tazobactam and meropenem, highlighting the effect of protocol nonadherence/missing data on outcomes in MITT patients. (Success rates in cUTI ME patients were 7% higher with ceftolozane/tazobactam than with levofloxacin.) Further, since moderate RI patients had worse treatment outcomes overall, the small sample sizes and greater number of RI patients receiving ceftolozane/ tazobactam may have led to larger confidence intervals around the clinical cure rate. All patients received the appropriate FDA-approved ceftolozane/tazobactam doses adjusted for degree of RI. Population pharmacokinetic analyses demonstrated that these ceftolozane/ tazobactam dosing regimens, now approved in patients with mild, moderate or severe RI, result in > 91% target attainment for bactericidal activity at MICs corresponding to susceptibility breakpoints for Enterobacteriaceae and P. aeruginosa (data on file).
The lower overall efficacy observed in moderate RI patients is consistent with other antibacterial clinical trial data. [7] [8] [9] [10] [11] [12] In a Phase 3 cIAI ceftazidime/avibactam trial, for instance, TOC response rates were lower in moderate RI mMITT patients, more so with ceftazidime/avibactam (45.2% versus 85.0%, respectively) than meropenem (74.3% versus 86.1%, respectively). Since this difference was attributed to ceftazidime/avibactam underdosing in moderate RI, revised dose adjustments for RI were established to improve drug plasma levels for target attainment. 7, 11, 12 Further analyses of these trials to assess differences in patient populations between treatment arms are needed.
Three published case studies reported successful ceftolozane/ tazobactam use in RI patients with MDR P. aeruginosa.
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Patel et al. 15 described a patient with a history of chronic kidney disease and a presumed genitourinary infection, who achieved clinical cure with ceftolozane/tazobactam. Similar successes in critically ill patients with presumed pneumonia and receiving continuous venovenous haemodiafiltration have been reported. 14, 15 Our analysis has certain limitations: (i) the small sample size ($6%) of patients with moderate RI relative to the entire cohort (however, the CL CR groups and analyses of outcome evaluations in RI patients were defined a priori in the clinical trials and SAPs); and (ii) the Cockcroft-Gault formula for calculating CL CR only estimates clearance and may not always yield accurate results, especially in the elderly, where the variables affecting creatinine tend to be more pronounced due to comorbid conditions.
In conclusion, cIAI and cUTI patients with moderate RI were older and had more underlying comorbidities. Since these factors were associated with increased likelihood of clinical failure, they likely contributed significantly to the worse treatment outcomes observed in those patients. While cIAI patients with moderate RI receiving ceftolozane/tazobactam had lower treatment success rates compared to meropenem in the MITT analysis, this difference was attributed to treatment-arm imbalances in numbers of RI patients and RI patients with indeterminate responses.
Funding
This work was supported by Merck & Co., Inc., Kenilworth, NJ, USA, which provided financial support for these analyses and for both of the original clinical trials. 
Transparency declarations
